Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
28.96
+0.51 (1.78%)
Nov 21, 2024, 12:53 PM EST - Market open

Company Description

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions.

It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett’s esophagus.

In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.

It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Castle Biosciences, Inc.
Castle Biosciences logo
Country United States
Founded 2007
IPO Date Jul 25, 2019
Industry Diagnostics & Research
Sector Healthcare
Employees 610
CEO Derek Maetzold

Contact Details

Address:
505 South Friendswood Drive, Suite 401
Friendswood, Texas 77546
United States
Phone 866 788 9007
Website castlebiosciences.com

Stock Details

Ticker Symbol CSTL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001447362
CUSIP Number 14843C105
ISIN Number US14843C1053
Employer ID 77-0701774
SIC Code 8071

Key Executives

Name Position
Derek J. Maetzold Founder, Chief Executive Officer, President and Director
Frank Stokes Chief Financial Officer and Treasurer
Kristen M. Oelschlager R.N. Chief Operating Officer
Tobin W. Juvenal Chief Commercial Officer
Camilla Zuckero Vice President of Investor Relations and Corporate Affairs
Kevin Doman Vice President of Sales
Keli Greenberg Vice President of Human Resources and Executive Director of Human Resources
Dr. Matthew Goldberg M.D. Senior Vice President of Medical
Bernhard E. Spiess Company Secretary

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 144 Filing
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 144 Filing
Nov 4, 2024 10-Q Quarterly Report
Nov 4, 2024 8-K Current Report
Nov 1, 2024 144 Filing
Oct 7, 2024 144 Filing
Sep 9, 2024 144 Filing
Aug 23, 2024 144 Filing